Evidence map›Paper›PMID 34180767›Full record

ArticleLeukemia & lymphoma2021

Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality.

Maximilian Stahl, Varun Narendra, Justin Jee, Andriy Derkach, Molly Maloy, Mark B Geyer, Anthony R Mato, Lindsey E Roeker, Martin S Tallman, Gunjan L Shah and 2 more

Abstract read
In one paragraph

Article in Leukemia & lymphoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maximilian StahlDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Varun NarendraDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Justin JeeDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andriy DerkachDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Molly MaloyDepartment of Health Informatics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mark B GeyerDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5248-9117
Anthony R MatoDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lindsey E RoekerDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Martin S TallmanDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gunjan L ShahDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Anthony DaniyanDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aaron D GoldbergDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Investigational Cancer Therapeutics Training Program (ICTTP)T32CA009207 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Omar Abdel-Wahab, Alexander Drilon · 1985 to 2026
$13.7M
CLINICAL SCHOLARS BIOMEDICAL RESEARCH TRAINING PROGRAMT32CA009512 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Ping Chi · 1985 to 2026
$6.3M
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA009207NCI NIH HHS T32 CA009512NCI NIH HHS T32 CA009512-31
6 · The paper itself

Abstract

Patients with hematological malignancies are at risk for poor outcomes when diagnosed with coronavirus disease 2019 (COVID-19). It remains unclear whether cytopenias and specific leukemia subtypes play a role in the clinical course of COVID-19 infection. Here, we report outcomes and their clinical/laboratory predictors for 65 patients with acute and chronic leukemias diagnosed with COVID-19 between 8 March 2020 and 19 May 2020 at Memorial Sloan Kettering Cancer Center in New York City. Most patients had CLL (38%) or AML (26%). A total of 14 (22%) patients required high flow nasal cannula or were intubated for mechanical ventilation and 11 patients (17%) died. A diagnosis of AML (OR 4.7,

Indexed as

COVID-19Leukemia, Myeloid, AcuteNeutropeniaAdultCOVID-19 TestingHumansRisk FactorsSARS-CoV-2COVID-19leukemiaSARS-CoV-2

Identifiers

PMID34180767
PMCPMC10080398

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.